← All trials
NCT00823550
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2009
- Primary completion
- Jul 1, 2014
- Completion date
- Jul 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 462
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Yonsei UniversityLead sponsor
- Yonsei UniversityStudy director
- Yonsei UniversityStudy chair
- Bristol-Myers SquibbCollaborator
- Kangbuk Samsung HospitalCollaborator
- Ajou UniversityCollaborator
- Korea UniversityCollaborator
- Hanyang UniversityCollaborator
- Inje UniversityCollaborator
- Catholic University of KoreaCollaborator
- Yonsei UniversityCollaborator
- Keimyung UniversityCollaborator
- Konkuk UniversityCollaborator
- Hallym UniversityCollaborator
- Inha UniversityCollaborator
- Kyungpook UniversityCollaborator
- Soonchunhyang UniversityCollaborator
- Chung-Ang UniversityCollaborator
- Pusan National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.